Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centric, Randomized, Double-Blind, Placebo-controlled, Phase-III Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent to be Used as an Adjuvant to Standard Treatment of Hypovolemic Shock

NCT05251181 is registered in ClinicalTrials.gov with Pharmazz, Inc. as lead sponsor.

NCT NCT05251181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05251181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centric, Randomized, Double-Blind, Placebo-controlled, Phase-III Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent to be Used as an Adjuvant to Standard Treatment of Hypovolemic Shock
Lead sponsor
Pharmazz, Inc.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
February 28, 2027
Completion date
October 31, 2028
Enrollment
430 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypovolemic shock